Sirtris Pharmaceuticals Inc., a biopharmaceutical company engaged in developing small molecule drugs that target the sirtuins, a recently discovered family of seven enzymes associated with the aging process, was acquired by GlaxoSmithKline (NYSE: GSK) in June of 2008 and now operates as the company’s wholly-owned subsidiary. Sirtris is focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases, such as Type 2 Diabetes, and various forms of cancer, as well as mitochondrial, inflammatory, neurodegenerative and cardiovascular diseases.
CSRHub includes data on Community, corporate governance, socially responsible investing, Governance, Sustainable Accounting Standards Board, and Bcorp.